Cargando…

Role of micro-RNAs 21, 124 and other novel biomarkers in distinguishing between group 1 WHO pulmonary hypertension and group 2, 3 WHO pulmonary hypertension

BACKGROUND: Pulmonary hypertension “PH” is considered a serious cardiovascular disease. World Health Organization divided PH into groups depending on many factors like pathological, hemodynamic, and clinical pictures. Lately, various micro-RNAs “miRNAs” and other novel biomarkers like endoglin and a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dimitry, Mark O., Soliman, Youssef M. A., ElKorashy, Reem I., Raslan, Hala M., Kamel, Solaf A., Hassan, Eman M., Ahmed, Fatma Elzahraa, Yousef, Rasha N., Awadallah, Eman A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468479/ https://www.ncbi.nlm.nih.gov/pubmed/37646902 http://dx.doi.org/10.1186/s43044-023-00395-w

Ejemplares similares

Predictors of pulmonary hypertension in patients with hypersensitivity pneumonitis
por: Elnady, Mohamed Abdelhakim, et al.
Publicado: (2023)

Impact and predictors of outcome of COVID-19 in pulmonary hypertension patients
por: Soliman, Y. M. A., et al.
Publicado: (2022)

Comparison of obstructive sleep apnoea prevalence and severity across WHO pulmonary hypertension groups
por: Simonson, Joseph L, et al.
Publicado: (2022)

Distinct plasma gradients of microRNA-204 in the pulmonary circulation of patients suffering from WHO Groups I and II pulmonary hypertension
por: Estephan, Leonard E., et al.
Publicado: (2019)

Pulmonary hypertension, how to diagnose and who to treat?
por: Roos-Hesselink, J. W., et al.
Publicado: (2011)

Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary Hypertension Association Registry
por: Fakhri, Shoaib, et al.
Publicado: (2020)

Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups
por: Chebib, Nader, et al.
Publicado: (2018)

Pentraxin 3: A Potential Novel Predictor for Neonatal Pulmonary Hypertension
por: Wakeel, Maged A. El, et al.
Publicado: (2019)

Beyond the Diagnosis of Group IV Pulmonary Hypertension: Chronic Thromboembolic Pulmonary Hypertension Mimickers
por: Chima, Noor Rehman, et al.
Publicado: (2020)

Group 3 pulmonary hypertension: Challenges and opportunities
por: McGettrick, Michael, et al.
Publicado: (2020)

The Biological Bases of Group 2 Pulmonary Hypertension
por: Fernández, Ana I., et al.
Publicado: (2019)

Everyday life experiences of spouses of patients who suffer from pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
por: Ivarsson, Bodil, et al.
Publicado: (2019)

Increased pulmonary serotonin transporter in patients with chronic obstructive pulmonary disease who developed pulmonary hypertension
por: Frille, Armin, et al.
Publicado: (2020)

Mechanisms Contributing to the Dysregulation of miRNA-124 in Pulmonary Hypertension
por: Zhang, Hui, et al.
Publicado: (2021)

The WHO classification of pulmonary hypertension: A case-based imaging compendium
por: Ryan, John J., et al.
Publicado: (2012)

Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction
por: Hinkamp, Colin A., et al.
Publicado: (2021)

Clinical Outcomes and Treatment Options in Patients With Pulmonary Hypertension Who Received Pulmonary Hypertension-Specific Drugs　― Single-Center Case Series ―
por: Kamiya, Chiaki, et al.
Publicado: (2019)

Epidemiology, Pathogenesis, and Clinical Approach in Group 5 Pulmonary Hypertension
por: Al-Qadi, Mazen, et al.
Publicado: (2021)

Advanced risk stratification of intermediate risk group in pulmonary arterial hypertension
por: Yogeswaran, Athiththan, et al.
Publicado: (2020)

Safety and Efficacy of Sildenafil for Group 2 Pulmonary Hypertension in Left Heart Failure
por: Desai, Kinjal, et al.
Publicado: (2023)

Magnetic resonance lymphangiography in group 1 paediatric pulmonary arterial hypertension
por: Juaneda, Ernesto, et al.
Publicado: (2021)

Attitudes towards exercise among medical specialists who manage patients with pulmonary hypertension
por: Chia, Karen S. W., et al.
Publicado: (2020)

Pulmonary hypertension concurrent with pericardial effusion and superior vena cava syndrome: who is the initiator?
por: WANG, Bei-Ning, et al.
Publicado: (2020)

Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension
por: Nikkho, Sylvia M., et al.
Publicado: (2022)

Pulmonary hypertension
por: Vonk Noordegraaf, Anton, et al.
Publicado: (2016)

Serious illness conversations in pulmonary hypertension
por: Ismail, Reem, et al.
Publicado: (2021)

Outcomes After Supraventricular Tachycardia Ablation in Patients With Group 1 Pulmonary Hypertension
por: Satish, Tejus, et al.
Publicado: (2023)

Regional Variation in Methamphetamine-associated Pulmonary Arterial Hypertension: Who’d Better Call Saul?
por: Prohaska, Clare C., et al.
Publicado: (2021)

Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative ‐ Group 3 Pulmonary Hypertension
por: Piccari, Lucilla, et al.
Publicado: (2023)

Pulmonary hypertension complicating pulmonary sarcoidosis
por: Huitema, M. P., et al.
Publicado: (2016)

Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pregnancy in pulmonary hypertension
por: Khan, Javed, et al.
Publicado: (2014)

Differences in the expression of DNA methyltransferases and demethylases in leukocytes and the severity of pulmonary arterial hypertension between ethnic groups
por: D’Addario, Catherine A., et al.
Publicado: (2022)

Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: An Immunological Perspective
por: Koudstaal, Thomas, et al.
Publicado: (2020)

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Humbert, Marc, et al.
Publicado: (2019)

Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Biomarkers in pulmonary arterial hypertension
por: Minai, Omar A.
Publicado: (2014)

Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension
por: Nathan, Steven D., et al.
Publicado: (2022)

Pulmonary Hypertension Associated Genetic Variants in Sarcoidosis Associated Pulmonary Hypertension
por: Groen, Karlijn, et al.
Publicado: (2022)

Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Chronic thromboembolic pulmonary hypertension
por: Mayer, Eckhard, et al.
Publicado: (2014)

Pulmonary Hypertension
por: Basyigit, Ilknur, et al.
Publicado: (2012)

Pulmonary venous remodeling in COPD-pulmonary hypertension and idiopathic pulmonary arterial hypertension
por: Andersen, Kasper Hasseriis, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ct5imrp9njp7tkc41gec6c1obr